I en interimanalyse baseret på 947 randomiserede patienter blev der observeret forkortet progressionsfri overlevelsestid og forøget antal dødsfald hos patienter, der fik Vectibix sammen med bevacizumab og kemoterapi.
In an interim analysis based on 947 randomized patients, shortened progression free survival time and increased deaths were observed in the patients receiving Vectibix in combination with bevacizumab and chemotherapy.